Deerfield
About Deerfield

Launched in 1994, Deerfield Management Company is an investment firm dedicated to advancing healthcare through information, investment, and philanthropy—all toward the end goal of cures for disease, improved quality of life, and reduced cost of care.

Read More
---
Investment

Supporting companies across the healthcare ecosystem with flexible funding models…

Read More
---
Information

Delivering market research to the Deerfield team, its portfolio companies and other partners.

Read More ---
Philanthropy

A New York City-based not-for-profit devoted to advancing innovative health care initiatives.

Read More
---
Portfolio Companies

Deerfield generally maintains a combined portfolio of more than 150 private and public investments across the life science, medical device, diagnostic, digital health and health service industries at all stages of evolution from start-up to mature company.

Read More View Portfolio Companies
---
Research Collaborations

Deerfield partners with leading academic research centers, providing critical funding and expertise to further sustain and accelerate the commercialization of discoveries toward meaningful societal impact by advancing cures for disease.

Read More View Research Collaborations
---
Strategic Partners

As a strategic partner, Deerfield offers capital, scientific expertise, business operating support, and unique access to innovation.

Read More
---
Deerfield Foundation

The Deerfield Foundation is a New York City-based not-for-profit organization whose mission is to improve health, accelerate innovation and promote human equity.

Read More Meet the Foundation Team
---
Cure Campus

Cure is a 12-story innovations campus in New York City that intends to bring together innovators from academia, government, industry, and the not-for-profit sectors to advance human health and accelerate the fight against disease.

Read More Join the Cure Email List
Cure Programming

Cure has a series of expert lectures intended to advance thought in healthcare, management, innovation, policy, and other relevant subjects. This fosters growth and education for those at Cure and its guests.

Events at the Cure

Zhen Zeng, Ph.D.

Zhen Zeng, Ph.D., is a Principal on the Public Structured Finance team. He joined the Firm in 2021 working as a Biostatistician on the Therapeutics team. Prior to Deerfield, Dr. Zeng spent over two years as Vice President of Biotechnology Equity Research at Morgan Stanley. Before Morgan Stanley, he worked as a Senior Scientist at Merck for more than three years. Dr. Zeng holds a B.E. in Bioengineering from the Harbin Institute of Technology, an M.S. in Biochemistry and Molecular Biology from Shanghai Jiao Tong University, an M.S. in Human Genetics from the University of Pittsburgh and a Ph.D. in Biostatistics from the University of Pittsburgh.

Elise Wang

Elise Wang is a Partner and Head of Private Equity Capital Markets on the Public Structured Finance team and joined the Firm in 2010. Ms. Wang provides extensive research and analysis on individual companies operating in the healthcare industry in both the US and Europe. Ms. Wang is a board member of Jaguar Gene Therapy. Prior to Deerfield, Ms. Wang was a Senior Research Analyst and Managing Director covering the biotechnology sector at PaineWebber and Citigroup. She began her career in healthcare as a venture capitalist and banker at PaineWebber and was an officer of PaineWebber Development Corporation, which managed nearly $1 billion in assets representing three PaineWebber funds and several research and development limited partnerships (RDLPs) invested in biotechnology and high technology companies. Ms. Wang holds an A.B. in Engineering Sciences with a specialty in Biomechanics from Harvard University and an M.B.A. from Harvard Business School.

Sumner Anderson

Sumner Anderson is a Partner on the Public Structured Finance team. Mr. Anderson joined the Firm in 2012 as a member of the Therapeutics team, providing extensive research and analysis on individual companies operating in the healthcare industry. He transitioned to the Public Structured Finance team in 2019. Prior to Deerfield, Mr. Anderson was a research analyst covering pharmaceuticals at Millennium Management. Before Millennium, he was a Managing Director in healthcare investment banking at Wells Fargo Securities and a pharmaceutical analyst in Global Equities at Citadel Investment Group. Mr. Anderson’s healthcare investment career has been split between investment banking and equity long short funds. He holds an A.B. in History and Economics from Harvard University, and an M.B.A. with an emphasis in Finance and Accounting from New York University.